Use of recombinant alpha 1-adrenoceptors to characterize subtype selectivity of drugs for the treatment of prostatic hypertrophy

European Journal of Pharmacology
R FoglarG Tsujimoto

Abstract

Several alpha 1-adrenoceptor antagonists have recently been developed for the treatment of benign prostatic hypertrophy because of their less frequent systemic side-effects compared to conventional alpha 1-adrenoceptor blockers. One potential explanation for their good tolerability would be the selectivity for a certain subtype of alpha 1-adrenoceptor. Utilizing COS-7 cells expressing the rat alpha 1A, the hamster alpha 1B and the human alpha 1C-adrenoceptors, we investigated affinities of alfuzosin, doxazosin, terazosin, indoramin and (+)- and (-)-5-[2-[[2-(o-ethoxyphenoxy)ethyl] amino]propyl]-2-methoxybenzesulfonamide HCl (YM 617) compared to prazosin. Radioligand binding studies showed that the affinities of alpha 1-adrenoceptor subtypes for alfuzosin (Ki value; alpha 1A: 2.4 nM, alpha 1B:1.4 nM, alpha 1C:4.2 nM), doxazosin (Ki value; alpha 1A:2.7 nM, alpha 1B:3.2 nM, alpha 1C:7.5 nM), terazosin (Ki value; alpha 1A:2.5 nM, alpha 1B:2.7 nM, alpha 1C:7.1 nM), indoramin (Ki value; alpha 1A:69 nM, alpha 1B:21 nM, alpha 1C:13 nM) and prazosin (Ki value; alpha 1A:0.16 nM, alpha 1B:0.19 nM, alpha 1C:0.2 nM) were equipotent to the three receptor subtypes. Unlike these antagonists, both (+)- and (-)-YM617 had relatively lower affinit...Continue Reading

References

Oct 1, 1992·British Journal of Urology·S N LloydK F Kyle
Sep 30, 1991·Biochemical and Biophysical Research Communications·J F BrunoM Berelowitz
May 1, 1991·British Journal of Urology·M A Stott, P Abrams
Jul 1, 1991·American Family Physician·W M O'Brien
Oct 12, 1991·Lancet·A JardinP Attali
Oct 1, 1988·Proceedings of the National Academy of Sciences of the United States of America·S CotecchiaB K Kobilka
Jan 1, 1981·Urological Research·A ShapiroM Caine
Aug 1, 1983·The Journal of Urology·H HedlundA Ek
Sep 1, 1980·Analytical Biochemistry·P J Munson, D Rodbard
Jan 1, 1993·Scandinavian Journal of Urology and Nephrology·M M ChristensenS E Husted
May 1, 1994·Clinical and Experimental Pharmacology & Physiology·S YamadaK Kawabe
Sep 15, 1993·Biochemical and Biophysical Research Communications·A HirasawaG Tsujimoto

❮ Previous
Next ❯

Citations

Feb 21, 2006·Naunyn-Schmiedeberg's Archives of Pharmacology·Martin C MichelMasao Sasamata
May 19, 2005·Journal of Cataract and Refractive Surgery·David F Chang, John R Campbell
Jun 4, 1999·European Journal of Pharmacology·P AlbertsM G Fredrickson
Dec 26, 2001·Urology·B Akduman, E D Crawford
Dec 26, 2001·Urology·M P O'Leary
Mar 20, 2002·The Journal of Clinical Investigation·Akito TanoueGozoh Tsujimoto
Nov 19, 2010·Journal of Medical Case Reports·Dileep Kumar, Fauzia Anis Khan
Aug 2, 2006·Biological & Pharmaceutical Bulletin·Gopal GargShailendra Saraf
Mar 25, 2008·Therapeutics and Clinical Risk Management·Angelo J Cambio, Christopher P Evans
Jul 29, 2003·Current Urology Reports·Chris M Gonzalez, Kevin T McVary
Apr 16, 2014·Cutaneous and Ocular Toxicology·Zeynep AktasBerati Hasanreisoglu
Apr 30, 2005·The Journal of Clinical Hypertension·William B White, Timothy Moon
Mar 16, 2006·The Journal of Pharmacy and Pharmacology·Akiyoshi OhtakeKeiji Miyata
Jul 13, 2011·British Journal of Clinical Pharmacology·Cees KorstanjeFrancisca L C van Doesum-Wolters
May 11, 2006·Current Medical Research and Opinion·Michael T FlanneryGary Ruoff
Dec 11, 2002·Expert Opinion on Pharmacotherapy·Jay KhastgirAnthony R Mundy
Jan 19, 2000·Nihon Ika Daigaku zasshi·K HoriuchiM Akimoto

❮ Previous
Next ❯

Related Concepts

Related Feeds

Adrenergic Receptors: Trafficking

Adrenergic receptor trafficking is an active physiological process where adrenergic receptors are relocated from one region of the cell to another or from one type of cell to another. Discover the latest research on adrenergic receptor trafficking here.